PROX1 and familial pancreatic carcinoma: The top 10 equivalently changed genes include some with known or suspected tumor relevance such as CYP3A5 (Noll et al., 2016), STEAP1 (Gomes et al., 2012), and PROX1 (Saukkonen et al., 2016), which are being investigated as drug targets for pancreatic cancer, GMNN (Kim et al., 2012; Kushwaha et al., 2016), which is associated with cancer pathophysiology and development, and SORBS2 (Alsafadi et al., 2011; Zhao et al., 2018; Lv et al., 2020; Lv et al., 2021), which is known to be associated with metastatic relapse.